High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients
Authors:
- 16 November 2015
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 154 (3) , 521-531
Abstract
It is speculated that adjuvant use of bisphosphonate reduces recurrence in breast cancer patients through suppression of bone resorption. To determine the prognostic impact of bone resorption markers, we investigated serum levels of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen (1CTP) and N-terminal crosslinking telopeptides of type I collagen (NTX). 1CTP and NTX were measured at baseline (before operation or neoadjuvant therapies) and afterward in 469 patients operated on breast cancer. The optimal cutoff value of 1CTP for relapse-free survival (RFS) was set at 3.6 ng/ml with an area under the receiver operating characteristics curve of 0.641 [95 % confidence interval (CI) = 0.560–0.721; p = 0.0011]. However, we were unable to determine a significant cutoff value for NTX. RFS was significantly worse for 1CTP-high patients with than for those with low levels of 1CTP (p = 0.0002). Multivariate analysis with tumor size, lymph node metastasis, and nuclear grade showed that 1CTP was a significant independent prognostic factor (hazard ratio = 2.04, 95 % CI = 1.13–3.68; p = 0.018). Worse prognosis for the subset with high 1CTP levels applied only to postmenopausal patients (p = 0.0002). RFS of 130 patients whose 1CTP changed from low at baseline to high at 6 months postoperatively showed RFS almost as poor as that for patients with high 1CTP throughout. These findings suggest that 1CTP may be useful not only for identifying patients with unfavorable prognosis, but also for selecting patients who may benefit from administration of bone-modifying agents in an adjuvant setting.Keywords
Funding Information
- Grant of Hyogo College of Medicine
This publication has 24 references indexed in Scilit:
- Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12Annals of Oncology, 2014
- Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trialThe Lancet Oncology, 2014
- Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysisJournal of Hematology & Oncology, 2013
- Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsAnnals of Oncology, 2012
- Breast-Cancer Adjuvant Therapy with Zoledronic AcidNew England Journal of Medicine, 2011
- Final 5‐year results of Z‐FAST trialCancer, 2011
- A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal WomenJournal of Bone and Mineral Research, 2005
- Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005Annals of Oncology, 2005
- Cellular and molecular mechanisms of action of bisphosphonatesCancer, 2000
- Mechanisms of bone metastasisCancer, 1997